MaxCyte Interim Revenue Rises But Loss Widens On CARMA Development
LONDON (Alliance News) - MaxCyte Inc on Monday said its loss widened in the first half of 2018 as it continued to invest in the development of its CARMA drug platform.The life sciences said Read More